Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Recruiting · Phase 2 · NCT04895436
Conditions: Chronic Lymphocytic Leukemia (CLL)
At a glance
- Research payments reported, 2025
- $214,177
- U.S. investigators named
- 9
- Sites paid
- 9
- Planned or actual enrollment
- 75
About the trial
- Sponsor
- AbbVie (with F. Hoffmann-La Roche Ltd, German CLL Study Group (GCLLSG), Dana-Farber Cancer Institute)
- Tested
- Venetoclax (drug), Obinutuzumab (drug)
- Dates
- Started 2022-03-28; completion 2029-01
- Results posted
- Not yet
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venet…
From ClinicalTrials.gov, last updated 2026-02-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $214,177 in research payments for this study in 2025 (29 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael Y. Choi, M.D. Hematology & Oncology · San Diego, CA
- Andres Chang, M.D./PH.D. Hematology & Oncology · Atlanta, GA
- Matthew S. Davids, M.D. Hematology & Oncology · Boston, MA
- Vijayalakshmi Donthireddy, M.D. Hematology & Oncology · Warren, MI
- Homam Alkaied, MD Hematology & Oncology · Duluth, MN
- John S. Hrom, MD Hematology & Oncology · Hattiesburg, MS
- Christopher E. Jensen, MD, MSCR Hematology & Oncology · Chapel Hill, NC
- Alan P. Zausner Skarbnik, MD Hematology · Charlotte, NC
- Douglas F. Beach, MD Hematology & Oncology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of North Carolina $59,837
- Hospital of Univ of Pennsylvania, PA $48,224
- Dana Farber Cancer Institute $46,195
- Emory University Hospital, GA $30,939
- Hattiesburg Clinic PA $12,000
- Henry Ford Health Hospital, MI $6,575
- Novant Health Huntersville Medical Center, NC $5,638
- St Lukes Hospital, MN $2,850
- Regents of the University of California the $1,918
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.